CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

The revised version of the vaccine, marketed as Spikevax, follows FDA guidance recommending that this year’s shots target ...

Moderna said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug ...

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were ...

U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Vaccine opponents and skeptics in charge of federal health agencies are restricting access to COVID shots that were a signature accomplishment of President Donald Trump’s first term.

The US Food and Drug Administration has ordered Pfizer and Moderna to expand their warning labels on COVID-19 vaccines.

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

The vaccines, appropriately celebrated as a first for mRNA technology, are also a milestone for the nanoparticle field. Although the first drug based on an LNP was approved by the US Food and Drug ...